On June 10, 2019, Mateon Therapeutics, Inc. announced resignation of Matthew Loar as its Chief Financial Officer effective June 30, 2019, and appointment of Amit Shah as its incoming Chief Financial Officer effective July 1, 2019. Until that time, Mr. Shah will provide his services to the Company as an independent contractor. Prior to working with and joining Mateon, Mr. Shah served as the CFO of Pioneer Medical Group.

On June 12, 2019, the Company's subsidiary Oncotelic, Inc. announced the formation of a Medical Advisory Board to provide strategic advice and guidance in connection with Oncotelic's efforts to advance its drug candidates for cancer treatment. Drs. Anatoly Dritschilo, David Horwitz, Reinhard von Roemeling and Stuart Siegel will provide expert advice and strategic guidance to advance the clinical development of the lead anti-cancer drug candidates of Oncotelic.

Dritschilo has over 35 years of experience as a physician-scientist and radiation oncologist, specializing in the treatment of breast and prostate cancer, radiation medicine, intraoperative radiation therapy, brachytherapy, 3D conformal radiotherapy, and development of radiation sensitizers for more effective cancer therapy. Dritschilo has served as Professor of Medicine and Molecular Immunology and Chief of Division of Rheumatology and Immunology at the University of Southern California (USC) Keck School of Medicine for 27 years. Currently, Dr. von Roemeling is the Senior Vice President, Clinical Development of Curis, Inc. Since 2011, Dr. Siegel has been the Chair of the Board of Directors of CureSearch, a national pediatric cancer research philanthropy, and Vice President of the Health Care Foundation of Ventura County.